This study investigated the acute effects of oxytocin (OT) on human aggression using a well-established laboratory measure of state (reactive) aggression to test the hypothesis that OT would decrease the frequency of aggressive responding. In a within-subject design, 17 healthy male volunteers received placebo or 24 IU of intranasal OT. Aggression was measured using the Point Subtraction Aggression Paradigm at 30 min before and 30, 60, and 90 min after dose. Acute OT did not produce a significant main effect on aggressive behavior. OT attenuated the expected rise in diastolic blood pressure from morning to early afternoon observed under placebo, providing a possible indication of biological activity. Examination of individual differences showed that aggressive responding following OT dosing (but not placebo) was positively correlated with psychometric measures of interpersonal manipulation and anger (Pearson's r = 0.57), indicating that higher scores on these antisocial personality traits were related to increased aggressive behavior following OT administration. These preliminary results stand in contrast to previous work on the prosocial effects of OT and highlight the need for further understanding of individual differences in aggression following OT administration. Such individual differences may have implications for the therapeutic use of OT in individuals with psychiatric disorders and dysfunctional social behavior. Behavioural Pharmacology 26:798-804
Introduction
Aggression represents a class of antisocial behavior that is prevalent in several psychiatric disorders (Lane et al., 2011; Alcorn et al., 2013; Beck and Heinz, 2013; Dack et al., 2013; Latalova et al., 2013; Coccaro et al., 2014) . In maladaptive and persistent forms (e.g. violent crime, child abuse), aggression places a heavy burden on medical and public health systems. Accumulating evidence supports the therapeutic potential of oxytocin (OT) in enhancing prosocial behavior and socioemotional processing. In humans, several studies have established that OT administration increases cooperation, trust, and generosity following acute administration (Kosfeld et al., 2005; Zak et al., 2007; Rilling et al., 2012) . Notably, each of these studies utilized a dose of 24 IU, delivered intranasally. Most human studies have used betweengroup designs and examined 24 IU as the active dose (Bakermans-Kranenburg and van IJzendoorn, 2013; Bethlehem, et al., 2013) . Collectively, the data suggest that OT administration enhances prosocial behaviors. Therefore, we examined the possibility of whether it could reduce antisocial behaviors such as aggression. This hypothesis has rarely been tested directly.
To our knowledge, only two previous human studies have examined the acute effects of OT on experimentally induced aggression. Campbell and Hausmann (2013) found an interaction effect in female participants responding on the Point Subtraction Aggression Paradigm (PSAP), such that OT (vs. placebo) moderated reactive aggression in women with high-state anxiety but not low-state anxiety. Using a within-subject design in the PSAP, Alcorn et al. (2015) investigated the effect of intranasal placebo, and 12, 24, and 48 IU of OT in six adult men with combined antisocial personality disorder (ASPD) and substance use disorder (SUD) . No orderly effects on aggressive behavior, measured by the PSAP, were observed under OT dose. Alcorn et al. (2015) investigated behavior at the individual-subject level, which revealed substantial dose-related variability in aggression (both increases and decreases) across participants, despite very stable monetary-earning (nonsocial) response patterns. Owing to the extreme, atypical life histories of aggressive and impulsive behavior among the participants enrolled by Alcorn et al. (2015) , it was unclear whether the observed variability was unique to this clinical population or was a feature of the effects of OT on aggression under laboratory conditions. The current within-subjects preliminary study was undertaken to determine the effects of acute OT administration on aggressive responding in healthy male participants without a history of psychiatric disorders and persistent aggression. As in the study by Alcorn et al. (2015) , we also focused on potentially relevant personality factors that might be associated with individual differences in the effects of OTspecifically, the antisocial personality traits of anger and interpersonal manipulation. These traits were selected for two reasons: (i) they are consistent with the clinical profile of individuals with ASPD and SUD (Ruiz et al., 2008; Burt, 2012; Alcorn et al., 2013) and (ii) individuals with higher levels of interpersonal manipulation and poor anger regulation demonstrate higher levels of aggression and violent behavior (Buss and Perry, 1992; Nouvion et al., 2007; Alia-Klein et al., 2009; Valliancourt and Sunderani, 2011) .
We hypothesized that acute OT administration would decrease aggressive responding on the PSAP. On the basis of previous studies (Alcorn et al., 2013 (Alcorn et al., , 2015 , we also examined the relationship between the personality traits (interpersonal manipulation and anger) and changes in aggression following OT dosing.
Methods
All experimental procedures were reviewed and approved by the University of Texas Health Science Center, Houston, Institutional Review Board. Informed consent was obtained from all participants before study participation.
Participants
Participants were recruited from a community sample through local newspaper advertisements. Potential participants (18-50 years of age) were first screened though an initial telephone interview to obtain information about recreational drug use, psychiatric, and medical history. Potentially eligible participants were scheduled for more extensive in-person screening. Before study participation all participants underwent a physical examination to screen for exclusionary medical conditions (e.g. HIV; seizures; cardiovascular, kidney, or endocrine diseases; diabetes; hypertension; and history of head trauma or loss of consciousness > 20 min) and current use of all prescription medications. Female participants were excluded from this experiment for two reasons: (i) the neuropeptide OT increases the levels of luteinizing hormone (Evans et al., 2003) , which could potentially affect the regularly occurring menstrual cycles in female participants, and (ii) currently there are no data on the interactions of administered OT with oral contraceptives (i.e. birth control), introducing the possibility of behavioral and physiological side-effects. All participants were interviewed by a trained mental health professional using the Structured Clinical Interview for DSM-IV (SCID) to assess for the diagnosis of Axis I disorders (First et al., 1996) and Axis II disorders (personality disorders; First et al., 1997) . SCID-I and SCID-II were used to ensure that none of the potential participants met DSM-IV criteria for any psychiatric disorder. All qualified participants were male, had no medical complication, and had no history of DSM-IV Axis I and/or DSM-IV Axis II personality disorders. The enrolled participants had a mean age of 32 years (SD = 9.2), with a mean of 13.6 years of education (SD = 2.1). Across participants, 53% were identified as African-American, 17.6% as Caucasian, and 29.4% as Hispanic.
Extraneous drug use was monitored through daily urine samples and expired alcohol breath samples before beginning participation. Urine samples were screened for extraneous drug use through the Enzyme Multiple Immunoassay Technique Drug Abuse Urine Assay (Innovacon, San Diego, California, USA). Expired breath samples were used for detecting alcohol consumption, before participation, and were analyzed using an Alcosensor III (Intoximeter, St. Louis, Missouri, USA). Psychoactive medication was prohibited during study participation, and caffeine consumption was prohibited on test days after entering the laboratory. No participant was positive for extraneous drug use or for expired blood alcohol content.
Procedure
Participants completed a minimum of four study days (1 day on which they were dosed with OT, 1 day on which they were dosed with placebo, and 2 days on which they were not dosed). To reduce variability in aggressive response patterns across doses (e.g. Alcorn et al., 2015) , stability criteria were required on separate nondosing days before the administration of OT and placebo (coefficient of variation < 0.25, with no monotonic upward or downward trend).
Participants came to the lab 2-4 days a week, from 08:00 h to~13:00 h each study day. Participants completed four sessions of the PSAP (Cherek, 1992) on each study day. On study days on which participants were dosed with OT or placebo, the first session was scheduled to occur at 08:30 h, 30 min before dose administration. The remaining three PSAP sessions were scheduled to occur at 30, 90, and 150 min after dosing. Each PSAP session lasted 25 min. The PSAP is a well-established and validated laboratory measure of human state aggression, the utility and experimental procedures of which have been documented across many studies, with demonstrated sensitivity to acute drug effects (Allen et al., 1997; Cherek et al., 1997 Cherek et al., , 2003 Cherek and Lane, 1999; Bjork et al., 2000; Lane and Cherek, 2000) .
Drug administration
Dose order was counterbalanced across all participants. Before drug administration, all participants were trained on the dosing procedures using 1.5 ml of saline to ensure accurate administration and comfort with the administration procedure. Participants were administered an intranasal dose (24 IU) of synthetic OT (Syntocinon, nasal spray; Novartis) or placebo by research personnel. The dose level of 24 IU was selected for two reasons: (i) this dose was within the range of doses (12, 24, and 48 IU) that were previously tested on human aggressive behavior (Alcorn et al., 2015) , and (ii) 24 IU is the most commonly used OT dose in human studies (reviewed in Bakermans-Kranenburg and van IJzendoorn, 2013; Shahrestani et al., 2013) . The drug administration apparatus was a 3 cm 3 (3 ml) needleless syringe attached to a nasal atomizer for intranasal administration. One spray was 4 IU, and each 4 IU spray is equivalent to 0.1 ml. Thus, 24 IU of OT is equivalent to 0.6 ml of nasal spray fluid. For drug preparation, OT doses were brought to their corresponding volumes (ml) in a 3 cm 3 needleless syringe, and then each syringe was brought to a full volume of 1.5 cm 3 by adding saline. This approach was used to blind participants to dose contents. The placebo dose contained only saline, and was also administered at a total volume of 1.5 ml (0.75 ml per nostril). Each dose of OT (24 IU OT) and placebo was administered at a total volume of 1.5 ml intranasally (∼0.75 ml per nostril) under the supervision of research personnel. All administrations were completed within 8 min. All participants inhaled the total volume of 1.5 ml within this time frame.
Behavioral measures
The dependent measure of aggression in the PSAP was the aggressive response rate (aggressive responses per minute). Aggressive responding was maintained on an FR10 schedule of responding. Aggressive responding was elicited by provocation, which occurred probabilistically on average every 125 s 20% and resulted in an ostensive loss of $0.15 from the participant's counter. These monetary loses (subtractions) were attributed to the fictitious individual paired with the participant. Participants were told that the other (fictitious) individual kept the money subtracted from their counters. The participant was informed that the money he subtracts from the fictitious individual's counter is not added to his own. Thus, the aggressive option was not maintained by monetary gain. The dependent measure of motor coordination (positive control) was the monetary response rate (monetary responses per second). Monetary responding was maintained on an FR100 (100 presses) schedule of responding, in which the participant gained $0.15 cents for each completed FR100. These two response options (aggressive and monetary responding) are measured in different response rate units because monetary responding occurs more frequently than aggressive responding during PSAP sessions (Lane and Cherek, 2000; Cherek et al., 2006) .
On days during which participants were given a dose of OT (24 IU) or placebo, aggressive response rates were measured at baseline (predose) and at each subsequent postdose session occurring 30, 90, and 150 min after dose administration (postdose sessions 1, 2, and 3, respectively). Behavioral data from each postdose session were normalized to the baseline (predose) session, and thus were calculated as a percent of the baseline predose response rate: [(postdose session response rate/predose session response rate) × 100].
Physiological measures
Blood pressure (BP) data were collected to provide confirmation of active OT. The participant's BP was measured using a sphygmomanometer (BpTru Vital Signs Monitor, Coquitlam, Canada) after each of the four PSAP sessions. BP data were collected to examine changes in autonomic nervous system activity after OT dosing, which can provide physiological confirmation of an active dose (Petersson et al., 1996) . All BP data were transformed into a difference score (Δ score)that is, postdose score − predose score.
Psychometric measures
The self-report psychopathy scale III
The self-report psychopathy scale III (SRP-III; Paulhus et al., 2010; Mahmut et al., 2011 ) is a self-report measure of the clinical construct of psychopathy. The SRP-III consists of 64-items which are scored on a 5-point Likert ratings scale ranging from 'disagree strongly' to 'agree strongly'. The SRP-III provides a total score in addition to four subscale scores measuring interpersonal manipulation, callous affect, erratic lifestyle, and criminal tendencies. The subscale of interpersonal manipulation was used for correlational analysis on the basis of the study by Valliancourt and Sunderani (2011) . The mean (raw) score on the interpersonal manipulation subscale was 11 (SD = 3).
The Buss-Perry aggression questionnaire
The Buss-Perry aggression questionnaire (BPAQ; Buss and Perry, 1992 ) is a self-report measure of trait aggression consisting of 29-items scored on a 5-point Likert ratings scale ranging from 'not like me at all' to 'a lot like me'. The BPAQ provides a total score in addition to four subscale scores measuring physical aggression, verbal aggression, anger, and hostility. The subscale of anger was used for correlational analysis on the basis of the study by Alia-Klein et al. (2009) . The mean (raw) score on the anger subscale was 35.8 (SD = 7.4).
Data analysis
All statistical tests were conducted using the statistical program STATA version 11.1 (STATACorp, College Station, Texas, USA). A two-way repeated-measures analysis of variance (ANOVA) tested for the main effects of dose and session, and the interaction of dose and session. The two within-subject factors were dose (placebo vs. OT) and session (postdose sessions 1-3). Statistical significance was set at P less than 0.05. The following dependent variables were analyzed in separate repeated-measures ANOVA models: aggressive response rates (percent of predose response), monetary response rates (percent of predose response), and Δ scores from all cardiovascular data. Dose and session were coded in as factors. To correct for violations against sphericity, P-values were corrected using the Huynh-Feldt epsilon correction. These corrected values were used to evaluate statistical significance. All ANOVA results are reported with the corrected P-values. If statistically significant results were found, follow-up post-hoc tests using Tukey's honest square difference (HSD; Tukey, 1949) were performed, with statistical significance set at P less than 0.05.
To explore the association between aggressive responding under OT and the personality traits of interpersonal manipulation (SRP-III) and anger (BPAQ), both psychometric scores were independently standardized to have a mean of 0 and an SD of 1. The standardized scores (z-scores) of interpersonal manipulation and anger were then added together to create a composite score, as the composite score was expected to provide a better profile of phenotypic heterogeneity than individual subscale scores (Crawford, 2003) . Correlational analysis exploring the association between aggressive responding (mean of the three postdose session change scores) and the combined personality trait score was carried out, with pairwise comparisons using Pearson's correlation coefficient.
One participant dropped out before receiving the placebo dose and completing the psychometric data. For this participant, the missing score was imputed using the placebo sample mean of the normalized aggressive response rate and the normalized cardiovascular data to provide nonbiased but balanced cells for statistical analysis. Psychometric scores were similarly imputed using the sample mean. For diastolic BP data (Δ scores), a statistically significant main effect of dose was observed [F(1,16) = 6.73, P = 0.01]; the main effects of session [F(2,32) = 0.83, NS] and the dose by session interaction [F(2,32) = 1.02, P = 0.37] were nonsignificant. Post-hoc analysis using Tukey's honest square difference revealed that diastolic BP was significantly lower (P < 0.05) following the OT dose versus placebo. Diastolic BP data (Δ scores) for OT and placebo across all postdose sessions are presented in Fig. 1 .
Results

Behavioral and cardiovascular data
Measures of central tendency and variance for normalized (percent of predose) aggressive response rates and monetary response rates, and cardiovascular data (Δ scores) are presented in Table 1 . Statistics of all raw PSAP and physiological data are presented in Table 2 . Importantly, baseline (predose) values of PSAP and BP data were similar, indicating that the observed effects on BP (and noneffects in PSAP) were not the result of differential predose values between placebo and OT.
Behavioral data and personality traits.
There was a statistically significant positive correlation between the mean aggressive response rates under OT (percent of predose; averaged across all postdose sessions) and the composite psychometric scores [r(16) = 0.57, P = 0.01]. A scatterplot of the mean aggressive response rates (percent of predose) and the composite psychometric scores is presented in Fig. 2 . To examine the possibility that this correlation was spurious, we examined the correlation between the composite psychometric scores and (i) baseline (pre-OT dose) aggressive responding, and (ii) aggressive responding without the imputed data points missing from one participant. The correlation with the baseline pre-OT dose session was r = − 0.34 (NS), indicating that the observed correlation with post-OT dose responding was not facilitated by the baseline (predose) level of aggressive responding. The correlation without the imputed scores was r = 0.48 (P < 0.05). This association was specific to the OT administration; there was no significant correlation between the mean aggressive response rates 
Discussion
This study utilized the PSAP to measure the acute effects of OT on the frequency of aggressive behavior in humans. The PSAP has an established utility in behavioral pharmacology, for example, demonstrating decreases in aggressive behavior following administration of serotonergic compounds (Cherek and Lane, 1999; 2001; Cherek et al., 2002) and increases in aggressive responding following testosterone administration (Kouri et al., 1995; Carré et al., 2009; . On the basis of multiple studies suggesting that acute OT increases the likelihood of prosocial behaviors such as cooperation and trust, we reasoned that OT would decrease operationally defined human aggression, a class of behavior that can be considered antisocial.
Contrary to our hypothesis, we observed no statistically significant main effect of OT on aggressive responding. There was a broad range of changes in aggressive responding on the PSAP under OT, including both increases and decreases, suggesting that individual differences played a role in moderating the effects. Similar (2) 5.6 (7) 150 (3) 4.4 (4) OT (24 IU) 30 (1) 0.2 (4) 90 (2) 1.1 (5) 150 (3) 2.8 (5) Response rates are normalized as percent of predose = (postdose session rate/ predose session rate) × 100. BP data are presented as Δ scores = postdose − predose. BP, blood pressure; IU, international unit; OT, oxytocin. effects were not observed for responding on the monetary optionresponse rates were highly stable across conditions, and there were no meaningful correlations between OT dosing and monetary responding. The absence of a main effect of OT dose on aggression is consistent with one of our previous observations in individuals with combined SUD and ASPD (Alcorn et al., 2013) and provides further support for the conclusion that individual differences in OT effects were specific to aggression rather than nonspecific effects on overall response rates (e.g. motor stimulation or sedation). More extensive work is needed to determine the factors that mediate (or moderate) individual differences in the response to OT. Alternatively, it is possible that features of the PSAP under the repeated testing protocol interact with acute OT in a manner that produces sufficient between-subject variability to obscure possible systematic effects. A study design that examined the role of personality factors in a moderation-based or mediationbased design (which would require a much larger sample size) could address this question more directly. It should be emphasized that our logic was based on the following idea: a compound that increases prosocial behaviors might be incompatible with (and might therefore decrease) an antisocial behavior such as aggression. However, these two classes of behaviors may also be orthogonal rather than inversely correlated, in which case OT could engender prosocial actions while having no effect on aggression. Further research would be necessary to test this possibility, and would need to examine OT-related changes in both prosocial and aggressive behaviors in a repeated-measures within-subject manner.
OT significantly modulated diastolic BP changes. Specifically, the known rise in BP from early morning to afternoon (Kaplan and Victor, 2010 )which was observed under placebo (see Tables 1 and 2)was attenuated following administration of OT. Very few human studies have provided biological verification of OT activity following intranasal administration. Even the least invasive method of verification requires repeated plasma sampling, which can be invasive to data collection in studies of laboratory behavior. Thus, although the modest sample size leaves this finding preliminary, the results imply that OT was biologically active, as previous work has also reported decreases in BP following OT administration (Petersson et al., 1996) .
The primary finding of interest was a positive correlation between the combined personality traits of interpersonal manipulation and anger, and aggressive responding following OT dosing, but not following placebo. This result is contrary to our prediction that individuals with the highest levels of antisocial traits would show the greatest reductions. This logic was based on the documented prosocial effects of OT in other social interaction paradigms such as the ultimatum game (Zak et al., 2007) . The current findings suggest that these antisocial personality traits (interpersonal manipulation and anger) might moderate the effects of OT on aggression. Importantly, Declerck et al. (2014) recently reported that the effects of OT on social interaction in the prisoner's dilemma task were dependent on prior interaction with the paired partner, such that with prior contact, OT enhanced cooperation, whereas without contact, OT increased competition (i.e. self-interested behavior). The present outcomes are generally consonant with those reported by Declerck et al. (2014) . Participants in the PSAP never meet the ostensible 'other' player; the task context only provides options of self-interest (monetary earning) or aggression (monetary subtraction), and OT enhanced aggression in those with greater antisocial traits.
Limitations of this preliminary study are related to the limited dose range, small sample size, and male-only participants, the latter precluding information on sex effects. An additional limitation is the generalizability of the positive correlation to populations with psychiatric disorders characterized by impulsive aggression. Additional research with these populations will be needed. In addition, the personality traits (anger and interpersonal manipulation) were selected on the basis of a statistical profile of ASPD + SUD individuals in the study by Alcorn et al. (2013) , as well as on the basis of previous studies in populations with psychiatric disorders (Alia-Klein et al., 2009; Valliancourt and Sunderani, 2011) . However, this particular combination of personality traits does not have validated utility in distinguishing clinically relevant groups, limiting generalizability.
Collectively, the results of this preliminary study (i) extend the data on acute OT effects in relation to moderating social behavior, (ii) elucidate sources of individual differences related to aggressive behavior in the context of OT, and (iii) tentatively suggest that OT may not be an efficacious therapeutic for managing impulsive aggression.
